Bioequivalence Study of Vildagliptin From Gliptus 50 mg Tablet (EVA Pharma, Egypt) and Galvus 50 mg Tablet (NOVARTIS PHARMA, GERMANY)

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2014
An open label randomized, single dose, two-way crossover bioequivalence study to determine the bioequivalence of Vildagliptin from Gliptus 50 mg tablet (EVA pharma, Egypt) and Galvus 50 mg tablet (NOVARTIS PHARMA, GERMANY) in Healthy Human Volunteers Under Fasting Condition
Epistemonikos ID: 55c15317bde67ed8418e83e1f8770b1595fe78ef
First added on: May 17, 2024